Oncocross 2026 Q1: Revenue Growth but Losses Widen, Net Debt Ratio Soars to 154%
Q1 2026 consolidated revenue 1.67B won (+167% YoY), operating loss 2.5B won (vs 2.4B), net loss 2.6B won (vs 2.3B) – losses widened
Issued 2nd series CB of 7B won (face value) in Feb 2026; conversion price refixed from 11,436 to 8,493 won due to stock price decline. Total CB face value 19.5B won
Net debt ratio surged to 154.3% (from 72.6% at end-2025). Total borrowings 19.5B won, cash 1.45B won
R&D expense 1.0B won (600% of revenue); no dividends or share buyback
Post-quarter: granted 360k stock options (12th series), announced absorption merger with Oncomaster to secure large-scale cancer patient data